Identification
- Generic Name
- Ecgonine
- DrugBank Accession Number
- DB01525
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Structure
Structure for Ecgonine (DB01525)
- Weight
- Average: 185.2203
Monoisotopic: 185.105193351 - Chemical Formula
- C9H15NO3
- Synonyms
- Not Available
- External IDs
- IDS-NE-001
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareIsocarboxazid The risk or severity of adverse effects can be increased when Ecgonine is combined with Isocarboxazid. Linezolid The risk or severity of adverse effects can be increased when Ecgonine is combined with Linezolid. Methylene blue The risk or severity of adverse effects can be increased when Ecgonine is combined with Methylene blue. Metoclopramide The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ecgonine. Minaprine The risk or severity of adverse effects can be increased when Ecgonine is combined with Minaprine. Moclobemide The risk or severity of adverse effects can be increased when Ecgonine is combined with Moclobemide. Nialamide The risk or severity of adverse effects can be increased when Ecgonine is combined with Nialamide. Pargyline The risk or severity of adverse effects can be increased when Ecgonine is combined with Pargyline. Phenelzine The risk or severity of adverse effects can be increased when Ecgonine is combined with Phenelzine. Procaine The risk or severity of adverse effects can be increased when Ecgonine is combined with Procaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tropane alkaloids. These are organic compounds containing the nitrogenous bicyclic alkaloid parent N-Methyl-8-azabicyclo[3.2.1]octane.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Tropane alkaloids
- Sub Class
- Not Available
- Direct Parent
- Tropane alkaloids
- Alternative Parents
- Piperidinecarboxylic acids / Beta hydroxy acids and derivatives / N-alkylpyrrolidines / Trialkylamines / Secondary alcohols / Cyclic alcohols and derivatives / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds show 4 more
- Substituents
- Alcohol / Aliphatic heteropolycyclic compound / Amine / Amino acid / Amino acid or derivatives / Azacycle / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative show 19 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- tropane alkaloid, 2-hydroxy monocarboxylic acid (CHEBI:4743)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DX2E9E17AV
- CAS number
- 481-37-8
- InChI Key
- PHMBVCPLDPDESM-FKSUSPILSA-N
- InChI
- InChI=1S/C9H15NO3/c1-10-5-2-3-6(10)8(9(12)13)7(11)4-5/h5-8,11H,2-4H2,1H3,(H,12,13)/t5-,6+,7-,8+/m0/s1
- IUPAC Name
- (1R,2R,3S,5S)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid
- SMILES
- [H][C@]12CC[C@]([H])([C@H]([C@@H](O)C1)C(O)=O)N2C
References
- Synthesis Reference
Lowell M. Somers, James E. Wynn, "Derivatives of benzoylecgonine, ecgonine and ecgonidine and methods for preparing and using same." U.S. Patent US5559123, issued December, 1985.
US5559123- General References
- Not Available
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 205 °C PhysProp water solubility 1.78E+005 mg/L YALKOWSKY,SH & DANNENFELSER,RM (1992) logS -0.02 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 1050.0 mg/mL ALOGPS logP -0.69 ALOGPS logP -3.1 Chemaxon logS 0.75 ALOGPS pKa (Strongest Acidic) 3.48 Chemaxon pKa (Strongest Basic) 9.69 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 60.77 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 46.57 m3·mol-1 Chemaxon Polarizability 18.7 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.6852 Blood Brain Barrier + 0.5115 Caco-2 permeable + 0.664 P-glycoprotein substrate Substrate 0.5177 P-glycoprotein inhibitor I Non-inhibitor 0.8611 P-glycoprotein inhibitor II Non-inhibitor 0.9927 Renal organic cation transporter Non-inhibitor 0.5846 CYP450 2C9 substrate Non-substrate 0.7356 CYP450 2D6 substrate Non-substrate 0.7702 CYP450 3A4 substrate Substrate 0.5536 CYP450 1A2 substrate Non-inhibitor 0.8342 CYP450 2C9 inhibitor Non-inhibitor 0.9417 CYP450 2D6 inhibitor Non-inhibitor 0.937 CYP450 2C19 inhibitor Non-inhibitor 0.9417 CYP450 3A4 inhibitor Non-inhibitor 0.9904 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9893 Ames test Non AMES toxic 0.76 Carcinogenicity Non-carcinogens 0.9692 Biodegradation Ready biodegradable 0.6439 Rat acute toxicity 2.5699 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9089 hERG inhibition (predictor II) Non-inhibitor 0.9244
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at July 31, 2007 13:10 / Updated at June 12, 2020 16:51